Seqens Seqens

X
[{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Enterade Clinical Study Demonstrates Fewer Stopped Treatments and Lower GI Side Effects for Cancer Patients","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for 02F3473H9O

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Enterade® (sodium chloride) advanced oncology formula (a plant-based amino acid beverage) helps in reducing adverse gastrointestinal side effects for patients undergoing cancer treatment.

            Lead Product(s): Sodium Chloride,Potassium Chloride,Magnesium Chloride

            Therapeutic Area: Gastroenterology Product Name: Enterade

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY